Opaleye Management Inc. - Dec 6, 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role
10%+ Owner
Signature
Opaleye Management, Inc. By: /s/ James Silverman President
Stock symbol
TCON
Transactions as of
Dec 6, 2022
Transactions value $
-$2,216
Form type
4
Date filed
12/8/2022, 05:49 PM
Previous filing
Nov 4, 2022
Next filing
Dec 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCON Common Stock, par value $0.01 per share Exercise of in-the-money or at-the-money derivative security $2.22K +222K +5.85% $0.01* 4.01M Dec 6, 2022 By Opaleye, L.P. F3
transaction TCON Common Stock, par value $0.01 per share Sale -$2.22K -1.54K -0.04% $1.44 4.01M Dec 6, 2022 By Opaleye, L.P. F1, F2, F3
holding TCON Common Stock, par value $0.01 per share 4.13M Dec 6, 2022 By Managed Account F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCON Prefunded Warrants Exercise of in-the-money or at-the-money derivative security -$2.22K -222K -11.72% $0.01* 1.67M Dec 6, 2022 Common Stock 222K $0.01 By Opaleye, L.P. F3, F5
holding TCON Prefunded Warrants 1.36M Dec 6, 2022 Common Stock 1.36M $0.01 By Opaleye, L.P. F3, F4, F5
holding TCON Prefunded Warrants 2.21M Dec 6, 2022 Common Stock 2.21M $0.01 By Opaleye, L.P. F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 6, 2022, the Reporting Person exercised prefunded warrants to purchase 221,539 shares of the Issuer's common stock for $0.01 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 1,539 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 220,000 shares.
F2 This disposition of shares by the Reporting Persons was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase by the Reporting Persons of 1,539 shares purchased on June 21, 2022 at a price of $1.3127 per share. The Reporting Persons have already sent the Issuer a check in the amount of $195.92, representing the full amount of the Reporting Person's pecuniary interest in the disgorgeable profit arising from such transactions.
F3 Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F4 Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F5 The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.